Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 284 results
A minimalist illustration of a pill and capsule against a dark background.

Jul 2, 2026

AI-driven Drug Discovery Faces 2026 Test

The landscape of AI-driven drug discovery is poised for a significant evaluation in 2026, as a cohort of AI-generated drugs is set to enter critical Phase 3 trials.In a recent analysis by Michael Santoro, a business ethics professor, the implications of substantial investments in AI for drug discovery are scrutinized. Notable examples include Xaira’s ambitious $1 billion launch and Alphabet’s Isomorphic Labs, which secured $600 million in funding. Santoro references a Boston Consulting Group stu
A minimalist illustration of a pill bottle and an AI brain in flat design.

Jul 2, 2026

How Indian Pharma Firms Are Using AI to Cut Drug Discovery Time

Indian pharmaceutical companies are increasingly leveraging artificial intelligence (AI) to enhance drug discovery processes, aiming to cut down the traditionally lengthy and costly timeline associated with bringing new medications to market.The pharmaceutical sector faces significant challenges due to the lengthy and expensive nature of drug development, which often spans over a decade and costs billions. AI and machine learning technologies are now being employed to streamline this process, en
A glass vial and syringe in a dimly lit lab setting

Jul 2, 2026

Indian pharma uses AI to cut development time and costs

AI is revolutionizing the pharmaceutical landscape in India by significantly reducing the time and costs associated with drug development. Traditionally, the drug development process in India could span over a decade and incur substantial financial burdens. However, the integration of artificial intelligence and machine learning is transforming this paradigm. Rather than displacing the workforce, Indian pharmaceutical companies are leveraging AI as a collaborative tool to tackle complex scientif
A genomic sequence on paper in a collaborative workspace

Jul 2, 2026

Claude Hackathon Supercharges Life Sciences

Claude has launched the Built with Claude Life Sciences hackathon, aimed at advancing AI applications in the life sciences sector. In partnership with Gladstone Institute, this global virtual event offers a $100,000 prize pool for participants utilizing Claude's specialized tools for research and coding.The hackathon is designed to enhance the integration of AI in life sciences by providing participants with access to Claude Science and Claude Code. These tools facilitate the analysis of biologi
A petri dish with cultured cells in a dim laboratory setting, illuminated by soft ambient light.

Jul 2, 2026

Insilico Medicine and Takeda join to accelerate AI-powered drug discovery

Insilico Medicine has partnered with Takeda to enhance drug discovery through AI technologies, aiming to streamline the development of new therapies.This collaboration will leverage Insilico’s Pharma.AI platform alongside Takeda’s drug development expertise to expedite the identification and advancement of new drug candidates across key therapeutic areas. The partnership focuses on improving the efficiency of early-stage drug discovery while enhancing the probability of developing medicines with
A minimalist illustration of a pill and a light bulb representing AI drug discovery.

Jul 2, 2026

Takeda Invests $600M in Insilico's AI Drug Discovery

Takeda is making a significant move in the realm of AI-driven drug discovery by partnering with Insilico Medicine in a deal potentially worth up to $600 million. This collaboration will leverage Insilico's Pharma.AI platform to identify new drug candidates across Takeda's extensive therapeutic portfolio.The agreement allows Insilico to receive approximately $60 million in upfront and near-term payments, with additional success-based milestones potentially raising the total to $600 million. Taked
A scientist's hand holding a molecular compound in a dimly lit lab.

Jul 2, 2026

Mankind Pharma Partners with Denovo Sciences to Advance AI-Led Drug Discovery

Mankind Pharma has teamed up with Denovo Sciences to enhance drug discovery through artificial intelligence, aiming to streamline the R&D process.This collaboration merges Mankind Pharma's extensive research and clinical development expertise with Denovo Sciences' advanced AI platform, which specializes in molecular generation and prioritization. The partnership adopts a human-in-the-loop approach, allowing AI to generate and assess molecular candidates while scientists refine these candidates t
Minimalist illustration of a molecular structure

Jul 2, 2026

Mankind Pharma, Denovo Sciences Join Forces for AI-Led Drug Discovery

Mankind Pharma has partnered with Denovo Sciences to enhance drug discovery through AI technology, signaling a significant advancement in their commitment to innovation in research and development.This collaboration combines Mankind Pharma’s robust research and development capabilities with Denovo Sciences’ AI-driven molecular generation platform. The partnership employs a human-in-the-loop model, where AI assists in generating and evaluating molecular candidates, while scientific experts provid
A laboratory vial filled with a colorful liquid on a shelf in a dimly lit lab.

Jul 2, 2026

Mankind Pharma joins hands with Denovo Sciences for AI-powered drug discovery

Mankind Pharma and Denovo Sciences are collaborating to enhance drug discovery through artificial intelligence. This partnership focuses on leveraging AI technology to streamline the drug development process. By combining AI capabilities with human expertise, Mankind Pharma and Denovo Sciences aim to reduce the time it takes to bring new drugs to market while simultaneously increasing the quality of candidates. The collaboration seeks to pinpoint the most promising drug options, thus optimizing
A minimalist representation of a drug molecule in flat design.

Jul 2, 2026

Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery

Insilico Medicine has entered a strategic partnership with Takeda to enhance drug discovery using AI technology.The collaboration focuses on leveraging Insilico's Pharma.AI platform to identify and develop novel drug candidates across Takeda's therapeutic areas. The goal is to utilize advanced generative models from the initial design stages to enhance the quality of drug candidates, ensuring they meet high efficacy and safety standards. Insilico will spearhead the AI-driven discovery process, w
A test tube on a lab bench in a research setting.

Jul 2, 2026

Anthropic debuts AI-driven pharma R&D tool, Claude Science

Anthropic has launched Claude Science, a new AI tool designed to enhance drug discovery workflows by integrating various research tools into a unified platform.This innovative application aims to streamline the fragmented processes in pharmaceutical research, enabling scientists to conduct multi-step studies more efficiently. Available for Linux and macOS, as well as through remote access, Claude Science is currently in beta testing and promises to consolidate resources such as PubMed, Jupyter,
A flat illustration of a drug molecule silhouette on a light gray background.

Jul 2, 2026

Insilico Medicine Partners with Takeda in AI Drug Discovery Deal Worth Up to $600 Million

Insilico Medicine has entered into a significant partnership with Takeda Pharmaceutical, aimed at enhancing drug discovery through AI technology. The collaboration, valued at up to $600 million, will utilize Insilico's generative AI platform to develop innovative drug candidates across various therapeutic areas.The agreement includes an initial payment and milestone payments totaling around $60 million, with the potential for further payments as specific development targets are met. Insilico's P